Literature DB >> 12202471

Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women.

Emmanuel Papadimitropoulos, George Wells, Beverley Shea, William Gillespie, Bruce Weaver, Nicole Zytaruk, Ann Cranney, Jonathan Adachi, Peter Tugwell, Robert Josse, Carol Greenwood, Gordon Guyatt.   

Abstract

OBJECTIVE: To review the effect of vitamin D on bone density and fractures in postmenopausal women. DATA SOURCE: We searched MEDLINE and EMBASE from 1966 to 1999 and examined citations of relevant articles and proceedings of international meetings. We contacted osteoporosis investigators and primary authors to identify additional studies and to obtain unpublished data. STUDY SELECTION: We included 25 trials that randomized women to standard or hydroxylated vitamin D with or without calcium supplementation or a control and measured bone density or fracture incidence for at least 1 yr. DATA EXTRACTION: For each trial, three independent reviewers assessed the methodological quality and abstracted data. DATA SYNTHESIS: Vitamin D reduced the incidence of vertebral fractures [relative risk (RR) 0.63, 95% confidence interval (CI) 0.45-0.88, P < 0.01) and showed a trend toward reduced incidence of nonvertebral fractures (RR 0.77, 95% CI 0.57-1.04, P = 0.09). Most patients in the trials that evaluated vertebral fractures received hydroxylated vitamin D, and most patients in the trials that evaluated nonvertebral fractures received standard vitamin D. Hydroxylated vitamin D had a consistently larger impact on bone density than did standard vitamin D. For instance, total body differences in percentage change between hydroxylated vitamin D and control were 2.06 (0.72, 3.40) and 0.40 (-0.25, 1.06) for standard vitamin D. At the lumbar spine and forearm sites, hydroxylated vitamin D doses above 50 microg yield larger effects than lower doses. Vitamin D resulted in an increased risk of discontinuing medication in comparison to control as a result of either symptomatic adverse effects or abnormal laboratory results (RR 1.37, 95% CI 1.01-1.88), an effect that was similar in trials of standard and hydroxylated vitamin D.
CONCLUSIONS: Vitamin D decreases vertebral fractures and may decrease nonvertebral fractures. The available data are uninformative regarding the relative effects of standard and hydroxylated vitamin D.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202471     DOI: 10.1210/er.2001-8002

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  61 in total

1.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

Review 2.  [Relative value of plain vitamin D and of biologically active vitamin D in the prevention and treatment of osteoporosis].

Authors:  S Scharla
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

3.  Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.

Authors:  Johann D Ringe
Journal:  Rheumatol Int       Date:  2004-10-13       Impact factor: 2.631

4.  Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.

Authors:  R Nuti; G Bianchi; M L Brandi; R Caudarella; E D'Erasmo; C Fiore; G C Isaia; G Luisetto; M Muratore; P Oriente; S Ortolani
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

5.  Canadian Consensus Conference on osteoporosis, 2006 update.

Authors:  Jacques P Brown; Michel Fortier; Heather Frame; André Lalonde; Alexandra Papaioannou; Vyta Senikas; Chui Kin Yuen
Journal:  J Obstet Gynaecol Can       Date:  2006-02

6.  Reporting of systematic reviews of micronutrients and health: a critical appraisal.

Authors:  Mei Chung; Ethan M Balk; Stanley Ip; Gowri Raman; Winifred W Yu; Thomas A Trikalinos; Alice H Lichtenstein; Elizabeth A Yetley; Joseph Lau
Journal:  Am J Clin Nutr       Date:  2009-02-25       Impact factor: 7.045

7.  Lack of generalizable evidence of the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis: comment on the article by Ringe et al.

Authors:  H Richard Barthel; Reinhold Vieth
Journal:  Rheumatol Int       Date:  2004-02-10       Impact factor: 2.631

Review 8.  Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.

Authors:  Toshio Matsumoto; Toshiyuki Takano; Hitoshi Saito; Fumiaki Takahashi
Journal:  Bonekey Rep       Date:  2014-03-05

9.  Effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in postmenopausal women with spondylosis.

Authors:  Naohisa Miyakoshi; Yoichi Shimada; Shigeru Ando; Takashi Minato; Eiji Itoi
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

10.  Dietary patterns associated with fall-related fracture in elderly Japanese: a population based prospective study.

Authors:  Yasutake Monma; Kaijun Niu; Koh Iwasaki; Naoki Tomita; Naoki Nakaya; Atsushi Hozawa; Shinichi Kuriyama; Shin Takayama; Takashi Seki; Takashi Takeda; Nobuo Yaegashi; Satoru Ebihara; Hiroyuki Arai; Ryoichi Nagatomi; Ichiro Tsuji
Journal:  BMC Geriatr       Date:  2010-06-01       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.